Pharmacy, Natural & Health Sciences

Pharmacy

Leadership Team Profiles

Michael-Bottorff

Michael B. Bottorff, Pharm.D., FCCP, FNLA, CLS
Chair, Department of Pharmacy Practice 
260-470-2651
mbbottorff@manchester.edu

Michael B. Bottorff, PharmD, is currently Professor and Chair in the Department of Pharmacy Practice at Manchester University Pharmacy Program in Fort Wayne, Ind.

After earning his doctorate in pharmacy from the University of Kentucky (1981) in Lexington, Dr. Bottorff completed his pharmacy residency there, serving as chief resident. He has held faculty positions at the University of Tennessee (1983-1989), the University of Cincinnati (1989-2009), the University of Charleston (2009-2011) and South College (2011-2015).

Dr. Bottorff’s research interests have focused on the clinical pharmacokinetics and pharmacodynamics of cardiovascular drugs, and he has served as principal or coprincipal investigator on numerous clinical trials. Dr. Bottorff has presented both nationally and internationally on such topics as drug therapy for acute coronary syndromes, management of dyslipidemias, understanding and predicting clinically important drug-drug interactions, and new strategies for managing atrial fibrillation.

Dr. Bottorff is a member of the editorial board of the Journal of Clinical Lipidology. He is also a reviewer of manuscripts submitted to The Annals of Pharmacotherapy, Archives of Internal Medicine, British Journal of Clinical Pharmacology, Pharmacotherapy, and The American Journal of Cardiology, among others. He has published over 85 original research articles, book chapters and refereed reviews, along with over 50 research abstracts. Dr. Bottorff is a member of the American Heart Association, and a Fellow of the American College of Clinical Pharmacy and the National Lipid Association. He has also served as Chairman of the National Pharmacy Cardiovascular Council and is certified as a Clinical Lipid Specialist.

Dr. Bottorff is a recognized specialist in cardiovascular therapeutics. He has assisted in the implementation of guideline-based therapies and served on the first national panel to develop guidelines for the management of heart failure for AHCPR.

Dr. Bottorff has published extensively on the impact of drug interactions on drug safety. Specifically, he authored the drug interaction paper for the National Lipid Association statin safety report, published in the American Journal of Cardiology in 2006 and updated in the Journal of Clinical Lipidology in 2014.